<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413852</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-201701-SQUID</org_study_id>
    <nct_id>NCT03413852</nct_id>
  </id_info>
  <brief_title>Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)</brief_title>
  <acronym>CHOICE</acronym>
  <official_title>Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Embo-Flüssigkeiten A.G.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Embo-Flüssigkeiten A.G.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to further establish that SQUID, an alternative liquid embolic&#xD;
      agent with specific properties, is a safe and effective alternative in bAVM endovascular&#xD;
      treatment strategy available to date. Therefore, the performance of SQUID will be documented&#xD;
      and its safety of use will be confirmed in current practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>modified Rankin Score (mRS)</measure>
    <time_frame>3 to 6 months after the last embolisation session</time_frame>
    <description>mRS is a scale used to measure the degree of handicap or dependence in daily activities of people who have suffered a stroke or other causes of neurological handicap.&#xD;
The scale ranges from 0 to 6, running from perfect health, without symptoms, to death.&#xD;
0 - No symptoms&#xD;
- No significant disability. Able to carry out all usual activities, despite some symptoms.&#xD;
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
- Moderate disability. Requires some help, but able to walk unassisted.&#xD;
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.&#xD;
- Death.</description>
  </primary_outcome>
  <enrollment type="Actual">111</enrollment>
  <condition>Cerebral Arteriovenous Malformation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SQUID non-adhesive liquid embolic agent</intervention_name>
    <description>AVM embolization using SQUID non-adhesive liquid embolic agent</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients planned for embolization using SQUID to achieve occlusion of a&#xD;
        previously untreated bAVM.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient planned for one or multiple embolization sessions using SQUID to achieve&#xD;
             occlusion of a previously untreated bAVM.*&#xD;
&#xD;
             *Patients with a direct fistula or saccular/flow-related aneurysm previously treated&#xD;
             with NBCA and/or coils may be included.&#xD;
&#xD;
          -  Patient in whom the use of SQUID had been decided for an embolization alone or in&#xD;
             association to neurosurgery or radiotherapy.&#xD;
&#xD;
          -  Patient ≥18 years old.&#xD;
&#xD;
          -  Patient or authorized representative dully informed and having no objection to the&#xD;
             clinical data collection and medical file access. An informed consent form must be&#xD;
             signed and dated whenever required by local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with bAVM not eligible for endovascular treatment.&#xD;
&#xD;
          -  Patient with bAVM previously treated by embolization with other devices (Liquid&#xD;
             embolic agent, NBCA, particles, and coils).*&#xD;
&#xD;
             *Patients with a direct fistula or saccular / flow-related aneurysm previously treated&#xD;
             with NBCA and/or coils may be included.&#xD;
&#xD;
          -  Patient with bAVM previously treated with surgery or radiotherapy.&#xD;
&#xD;
          -  Patient intended to undergo surgery and embolization during the same procedure at&#xD;
             first embolization&#xD;
&#xD;
          -  Patient with multiple bAVM or bAVM associated with dural arteriovenous Fistula*.&#xD;
&#xD;
             *Patients with a direct fistula or saccular / flow-related aneurysm previously treated&#xD;
             with NBCA and/or coils may be included.&#xD;
&#xD;
          -  Patient presenting contra-indication to the use of SQUID according to the Instructions&#xD;
             For Use.&#xD;
&#xD;
          -  Intention to treat with any non-adhesive embolic liquid other than SQUID, or planned&#xD;
             treatment with another non-adhesive embolic liquid over the course of the endovascular&#xD;
             treatment phase.&#xD;
&#xD;
          -  Patient planned for a total endovascular treatment phase duration exceeding 2 years.&#xD;
&#xD;
          -  Patient participating in another clinical study evaluating another medical device,&#xD;
             another procedure or a medication.&#xD;
&#xD;
          -  Any condition or any situation that would prohibit the patient from coming to the&#xD;
             investigational center for the follow-up as recommended by the study protocol between&#xD;
             3 and 6 months, or prohibit carrying out the telephone mRS assessments at 1 month&#xD;
             after each embolization session and at 12 months after the end of the endovascular&#xD;
             treatment phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr-Universität Bochum, Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gerardo Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

